The NY Times reports that a federal judge on Monday struck down patents on two genes linked to breast and ovarian cancer. The decision, if upheld, could throw into doubt the patents covering thousands of human genes and reshape the law of intellectual property.
U.S. Judge Invalidates Human Gene Patent
2 Comments
Recent Posts
The Law Bytes Podcast, Episode 280: A Fall Update on Where Things Stand on Canadian Digital Policy Reforms 
The Wrong Ban: The Heritage Committee Backed a Targeted Ad Ban for Kids and Stopped Short of a Social Media Ban, Yet the Government Chose the Reverse 
Regulator First, Rules Later: Bill C-34 Debate Shows the Government Wants a Digital Safety Commission Before It Figures Out What It Will Do 
Making the Case Against Its Own Bill: What the Government’s Bill C-34 Charter Statement Reveals About the Constitutional Vulnerability of the Social Media Ban 
“Position Has Not Changed”: The Canadian Government Reaffirms That Antisemitism Includes Anti-Zionism
“Myriad Genetics, the company that holds the patents with the University of Utah Research Foundation, asked the court to dismiss the case, claiming that the work of isolating the DNA from the body transforms it and makes it patentable. ”
So, they claim they aren’t actually patenting the two genes, they are patenting transformed version of the genes? To me this would invalidate the work of the human genome project, as they cataloged not the human genome but some variation thereof… Or am I understanding the claim incorrectly?
They’re claiming that isolated DNA is “transformed”, so the not-found-in-nature requirement of a patent doesn’t apply to the genes.